Lung Cancer: New Directions in Senior Patients Assessment
Abstract
:1. Introduction
Literature Search and Selection Methodology
2. Biomarkers and Biological Reactivity in Lung Cancer Senior Patients
2.1. Biomarkers Used in the Diagnosis, Prognosis, and Treatment of Lung Cancer
2.2. Biomarkers in Lung Cancer Specific to Geriatric Patients
2.2.1. MicroRNA
2.2.2. Circulating Tumor DNA
2.2.3. DNA Methylation Age of Blood
3. Performance Status, Nutritional Status, Albumin Levels, and Individualization of Therapeutic Approach
4. Geriatric Lung Cancer Screening Tools
4.1. Clinical Toolkits and Assessment Tools—Geriatric 8, Identification of Seniors at Risk—Hospitalized Patients (ISAR-HPs), and Comprehensive Geriatric Assessment (CGA)
4.2. The Role of Geriatric Screening Instruments in Lung Cancer Assessment
4.3. Other Screening Tools and Assessments
5. Discussion
5.1. The Implications of Biomarkers in Lung Cancer Management
5.1.1. Biomarkers Used in the Diagnosis, Prognosis, and Treatment of Lung Cancer
5.1.2. Biomarkers in Lung Cancer Specific to Geriatric Patients
- MicroRNA
- Circulating Tumor DNA
- DNA Methylation Age of Blood
5.2. Performance Status, Nutritional Status, Albumin Levels, and Individualization of Therapeutic Approach
5.3. The Value of Clinical Toolkits and Assessment Tools in Managing Senior Patients
5.3.1. The Role of Geriatric Screening Instruments in Lung Cancer Assessment
5.3.2. Other Screening Tools and Assessments
6. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Abraham, J.; Gulley, J.L.; Allegra, C.J. (Eds.) Bethesda Handbook of Clinical Oncology; Lippincott Williams & Wilkins: Philadelphia, PA, USA, 2000. [Google Scholar]
- Yang, C.J.; Brown, A.B.; Deng, J.Z.; Lui, N.S.; Backhus, L.M.; Shrager, J.B.; D’Amico, T.A.; Berry, M.F. The Oldest Old: A National Analysis of Outcomes for Patients 90 Years or Older with Lung Cancer. Ann. Thorac. Surg. 2020, 109, 350–357. [Google Scholar] [CrossRef] [PubMed]
- Lee-Chiong, T.L., Jr.; Matthay, R.A. Lung cancer in the elderly patient. Clin. Chest Med. 1993, 14, 453–478. [Google Scholar] [CrossRef] [PubMed]
- Wang, P.; Li, C.; An, Y.; Wang, X.; Liang, Z.; Chen, L. The management of elderly patients with lung cancer: A single center retrospective study. Ann. Palliat. Med. 2021, 10, 229–237. [Google Scholar] [CrossRef] [PubMed]
- Niederhuber, J.E.; Armitage, J.O.; Doroshow, J.H.; Kastan, M.B.; Tepper, J.E. Abeloff’s Clinical Oncology e-Book; Elsevier Health Sciences: Amsterdam, The Netherlands, 2013. [Google Scholar]
- Kerr, D.J.; Haller, D.G.; Van de Velde, C.J.; Baumann, M.; Saijo, N. Oxford Textbook of Oncology; Oxford University Press: Oxford, UK, 2016. [Google Scholar]
- Cho, J.H.; Lim, S.H.; An, H.J.; Kim, K.H.; Park, K.U.; Kang, E.J.; Choi, Y.E.; Ahn, M.S.; Lee, M.H.; Sun, J.M.; et al. Osimertinib for Patients with Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase II Trial (KCSG-LU15-09). J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2020, 38, 488–495. [Google Scholar] [CrossRef] [PubMed]
- Hurria, A.; Kris, M.G. Management of lung cancer in older adults. CA Cancer J. Clin. 2003, 53, 325–341. [Google Scholar] [CrossRef]
- Owonikoko, T.K.; Ragin, C.C.; Belani, C.P.; Oton, A.B.; Gooding, W.E.; Taioli, E.; Ramalingam, S.S. Lung cancer in elderly patients: An analysis of the surveillance, epidemiology, and end results database. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2007, 25, 5570–5577. [Google Scholar] [CrossRef] [PubMed]
- Brown, J.S.; Eraut, D.; Trask, C.; Davison, A.G. Age and the treatment of lung cancer. Thorax 1996, 51, 564–568. [Google Scholar] [CrossRef]
- Scott, A.; Salgia, R. Biomarkers in lung cancer: From early detection to novel therapeutics and decision making. Biomark. Med. 2008, 2, 577–586. [Google Scholar] [CrossRef] [PubMed]
- Levine, M.E.; Hosgood, H.D.; Chen, B.; Absher, D.; Assimes, T.; Horvath, S. DNA methylation age of blood predicts future onset of lung cancer in the women’s health initiative. Aging 2015, 7, 690–700. [Google Scholar] [CrossRef]
- Sauler, M.; Bucala, R.; Lee, P.J. Role of macrophage migration inhibitory factor in age-related lung disease. Am. J. Physiol. Lung Cell. Mol. Physiol. 2015, 309, L1–L10. [Google Scholar] [CrossRef]
- Ye, J.; Xu, M.; Tian, X.; Cai, S.; Zeng, S. Research advances in the detection of miRNA. J. Pharm. Anal. 2019, 9, 217–226. [Google Scholar] [CrossRef] [PubMed]
- Shields, M.D.; Chen, K.; Dutcher, G.; Patel, I.; Pellini, B. Making the Rounds: Exploring the Role of Circulating Tumor DNA (ctDNA) in Non-Small Cell Lung Cancer. Int. J. Mol. Sci. 2022, 23, 9006. [Google Scholar] [CrossRef] [PubMed]
- Sacco, P.C.; Maione, P.; Palazzolo, G.; Gridelli, C. Treatment of advanced non-small cell lung cancer in the elderly. Expert Rev. Respir. Med. 2018, 12, 783–792. [Google Scholar] [CrossRef] [PubMed]
- Thunnissen, E.; van der Oord, K.; den Bakker, M. Prognostic and predictive biomarkers in lung cancer. A Review. Virchows Arch. Int. J. Pathol. 2014, 464, 347–358. [Google Scholar] [CrossRef] [PubMed]
- Guven, D.C.; Sahin, T.K.; Erul, E.; Rizzo, A.; Ricci, A.D.; Aksoy, S.; Yalcin, S. The association between albumin levels and survival in patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis. Front. Mol. Biosci. 2022, 9, 1039121. [Google Scholar] [CrossRef]
- Seto, Y.; Kaneko, Y.; Mouri, T.; Fujii, H.; Tanaka, S.; Shiotsu, S.; Hiranuma, O.; Morimoto, Y.; Iwasaku, M.; Yamada, T.; et al. Prognostic factors in older patients with wild-type epidermal growth factor receptor advanced non-small cell lung cancer: A multicenter retrospective study. Transl. Lung Cancer Res. 2021, 10, 193–201. [Google Scholar] [CrossRef] [PubMed]
- Ikeda, S.; Yoshioka, H.; Ikeo, S.; Morita, M.; Sone, N.; Niwa, T.; Nishiyama, A.; Yokoyama, T.; Sekine, A.; Ogura, T.; et al. Serum albumin level as a potential marker for deciding chemotherapy or best supportive care in elderly, advanced non-small cell lung cancer patients with poor performance status. BMC Cancer 2017, 17, 797. [Google Scholar] [CrossRef]
- Heyman, N.; Tsirulnicov, T.; Ben Natan, M. Prediction of geriatric rehabilitation outcomes: Comparison between three cognitive screening tools. Geriatr. Gerontol. Int. 2017, 17, 2507–2513. [Google Scholar] [CrossRef]
- Bellera, C.A.; Rainfray, M.; Mathoulin-Pélissier, S.; Mertens, C.; Delva, F.; Fonck, M.; Soubeyran, P.L. Screening older cancer patients: First evaluation of the G-8 geriatric screening tool. Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. 2012, 23, 2166–2172. [Google Scholar] [CrossRef]
- Decoster, L.; Van Puyvelde, K.; Mohile, S.; Wedding, U.; Basso, U.; Colloca, G.; Rostoft, S.; Overcash, J.; Wildiers, H.; Steer, C.; et al. Screening tools for multidimensional health problems warranting a geriatric assessment in older cancer patients: An update on SIOG recommendations†. Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. 2015, 26, 288–300. [Google Scholar] [CrossRef]
- Almodovar, T.; Teixeira, E.; Barroso, A.; Soares, M.; Queiroga, H.J.; Cavaco-Silva, J.; Barata, F. Elderly patients with advanced NSCLC: The value of geriatric evaluation and the feasibility of CGA alternatives in predicting chemotherapy toxicity. Pulmonology 2019, 25, 40–50. [Google Scholar] [CrossRef]
- Schulkes, K.J.G.; Souwer, E.T.D.; van Elden, L.J.R.; Codrington, H.; van der Sar-van der Brugge, S.; Lammers, J.J.; Portielje, J.E.A.; van den Bos, F.; Hamaker, M.E. Prognostic Value of Geriatric 8 and Identification of Seniors at Risk for Hospitalized Patients Screening Tools for Patients With Lung Cancer. Clin. Lung Cancer 2017, 18, 660–666.e1. [Google Scholar] [CrossRef] [PubMed]
- Agemi, Y.; Shimokawa, T.; Sasaki, J.; Miyazaki, K.; Misumi, Y.; Sato, A.; Aida, S.; Ishii, M.; Nakamura, Y.; Naoki, K.; et al. Prospective evaluation of the G8 screening tool for prognostication of survival in elderly patients with lung cancer: A single-institution study. PLoS ONE 2019, 14, e0210499. [Google Scholar] [CrossRef] [PubMed]
- Cella, D.F.; Bonomi, A.E.; Lloyd, S.R.; Tulsky, D.S.; Kaplan, E.; Bonomi, P. Reliability and validity of the Functional Assessment of Cancer Therapy—Lung (FACT-L) quality of life instrument. Lung Cancer 1995, 12, 199–220. [Google Scholar] [CrossRef] [PubMed]
- Eton, D.T.; Cella, D.; Yount, S.E.; Davis, K.M. Validation of the functional assessment of cancer therapy--lung symptom index-12 (FLSI-12). Lung Cancer 2007, 57, 339–347. [Google Scholar] [CrossRef] [PubMed]
- Käsmann, L.; Janssen, S.; Rades, D. Karnofsky Performance Score, Radiation Dose and Nodal Status Predict Survival of Elderly Patients Irradiated for Limited-disease Small-cell Lung Cancer. Anticancer Res. 2016, 36, 4177–4180. [Google Scholar] [PubMed]
- Weizer, A.Z.; Joshi, D.; Daignault, S.; Kinnaman, M.; Hussain, M.; Montie, J.E.; Zhang, Y.; Lee, CT. Performance status is a predictor of overall survival of elderly patients with muscle invasive bladder cancer. J. Urol. 2007, 177, 1287–1293. [Google Scholar] [CrossRef] [PubMed]
- Ishida, T.; Yokoyama, H.; Kaneko, S.; Sugio, K.; Sugimachi, K. Long-term results of operation for non-small cell lung cancer in the elderly. Ann. Thorac. Surg. 1990, 50, 919–922. [Google Scholar] [CrossRef] [PubMed]
- Haynes, J.M. Pulmonary Function Test Quality in the Elderly A Comparison with Younger Adults. Respir. Care 2013, 59, 16–21. [Google Scholar] [CrossRef] [PubMed]
- Melo, S.M.D.; Oliveira, L.A.; Wanderley, J.L.F.; Rocha, R.D.A. Evaluating the extremely elderly at a pulmonary function clinic for the diagnosis of respiratory disease: Frequency and technical quality of spirometry. J. Bras. De Pneumol. Publicacao Of. Da Soc. Bras. De Pneumol. E Tisilogia 2019, 45, e20180232. [Google Scholar] [CrossRef]
- Decoster, L.; Kenis, C.; Schallier, D.; Vansteenkiste, J.; Nackaerts, K.; Vanacker, L.; Vandewalle, N.; Flamaing, J.; Lobelle, J.P.; Milisen, K.; et al. Geriatric Assessment and Functional Decline in Older Patients with Lung Cancer. Lung 2017, 195, 619–626. [Google Scholar] [CrossRef] [PubMed]
- Heckman, E.J.; O’Connor, G.T. Pulmonary function tests for diagnosing lung disease. Jama 2015, 313, 2278–2279. [Google Scholar] [CrossRef] [PubMed]
- Montgomery, G.; McPhee, J.; Pääsuke, M.; Sipilä, S.; Maier, A.B.; Hogrel, J.Y.; Degens, H. Determinants of Performance in the Timed Up-and-Go and Six-Minute Walk Tests in Young and Old Healthy Adults. J. Clin. Med. 2020, 9, 1561. [Google Scholar] [CrossRef] [PubMed]
- Mak, K.S.; van Bommel, A.C.; Stowell, C.; Abrahm, J.L.; Baker, M.; Baldotto, C.S.; Baldwin, D.R.; Borthwick, D.; Carbone, D.P.; Chen, A.B.; et al. Defining a standard set of patient-centred outcomes for lung cancer. Eur. Respir. J. 2016, 48, 852–860. [Google Scholar] [CrossRef] [PubMed]
- Barajas, G.; Zembower, T.; Silkaitis, C.; Brennan, J.; Brassil, E.; Nozicka, N.; Groth, M.; Ward-Fore, S.; Lau, M.; Sanders, L.; et al. Triage documentation-based decision support to improve infectious disease risk screening and mitigate exposure. Am. J. Infect. Control 2016, 44, 1063–1065. [Google Scholar] [CrossRef] [PubMed]
- Lalla, R.; Sammy, I.; Paul, J.; Nunes, P.; Ramcharitar Maharaj, V.; Robertson, P. Assessing the validity of the Triage Risk Screening Tool in a third world setting. J. Int. Med. Res. 2018, 46, 557–563. [Google Scholar] [CrossRef] [PubMed]
- Jain, K.K. Textbook of Personalised Medicine; Springer: New York, NY, USA, 2009. [Google Scholar]
- Chen, J.J.; Lin, W.J.; Chen, H.C. Pharmacogenomic biomarkers for personalized medicine. Pharmacogenomics 2013, 14, 969–980. [Google Scholar] [CrossRef] [PubMed]
- Barbareschi, M.; Barberis, M.; Buttitta, F.; Doglioni, C.; Fiorentino, M.; Fontanini, G.; Franco, R.; Marchetti, A.; Rossi, G.; Troncone, G. Predictive markers in lung cancer: A few hints for the practicing pathologist. Pathologica 2018, 110, 29–38. [Google Scholar] [PubMed]
- Bearz, A.; Berretta, M.; Cappellani, A.; Lleshi, A.; Berto, E.; Fratino, L.; Tirelli, U. Biomarkers in lung cancer. Front. Biosci. (Elite Ed.) 2010, 2, 1099–1104. [Google Scholar] [CrossRef]
- Pirker, R. Biomarkers for immune checkpoint inhibitors in advanced nonsmall cell lung cancer. Curr. Opin. Oncol. 2019, 31, 24–28. [Google Scholar] [CrossRef]
- Abe, S. Molecular biological prognostic markers in lung cancer. Nihon Geka Gakkai Zasshi 1997, 98, 2–7. [Google Scholar] [PubMed]
- Lindskog, C.; Edlund, K.; Mattsson, J.S.; Micke, P. Immunohistochemistry-based prognostic biomarkers in NSCLC: Novel findings on the road to clinical use? Expert Rev. Mol. Diagn. 2015, 15, 471–490. [Google Scholar] [CrossRef] [PubMed]
- De Maria, L.C., Jr.; Cohen, H.J. Characteristics of lung cancer in elderly patients. J. Gerontol. 1987, 42, 540–545. [Google Scholar] [CrossRef]
- Herbst, R.S.; Heymach, J.V.; Lippman, S.M. Lung cancer. N. Engl. J. Med. 2008, 359, 1367–1380. [Google Scholar] [CrossRef] [PubMed]
- Gridelli, C.; Rossi, A.; Maione, P.; Palazzolo, G.; Sacco, P.C.; Bareschino, M.A.; Schettino, C. Overview of clinical trials for lung cancer in the elderly. Aging Health 2008, 4, 629–642. [Google Scholar] [CrossRef]
- Trédaniel, J.; Savinelli, F.; Sergent, G.; Bousquet, G.; Le Maignan, C.; Hennequin, C.; Gossot, D.; Misset, J.L. Lung cancers in the elderly. Bull. Du Cancer 2008, 95, 57–64. [Google Scholar]
- North-Eastern Italian Oncology Group. Clinical characteristics, diagnosis and treatment of elderly patients with lung cancer at non-surgical institutions: A multicenter study. Neoplasms Elder. Comm. Tumori 1990, 76, 429–433. [Google Scholar]
- Gift, A.G.; Jablonski, A.; Stommel, M.; Given, C.W. Symptom clusters in elderly patients with lung cancer. Oncol. Nurs. Forum 2004, 31, 202–212. [Google Scholar] [CrossRef] [PubMed]
- O’Rourke, M.A.; Crawford, J. Lung Cancer in the Elderly. Clin. Geriatr. Med. 1987, 3, 595–623. [Google Scholar] [CrossRef]
- Kurtz, M.E.; Kurtz, J.C.; Stommel, M.; Given, C.W.; Given, B.A. Symptomatology and loss of physical functioning among geriatric patients with lung cancer. J. Pain Symptom Manag. 2000, 19, 249–256. [Google Scholar] [CrossRef]
- Health Commission of The People’s Republic of China. China, National guidelines for diagnosis and treatment of lung cancer 2022 in China (English version). Chin. J. Cancer Res. = Chung-Kuo Yen Cheng Yen Chiu 2022, 34, 176–206. [Google Scholar] [CrossRef] [PubMed]
- Jadhav, S.; Handa, A.; Kumar, S.; Chowdhury, G.S. Study of Clinical Presentations of Lung Cancer In tertiary Level Hospital 2022. Available online: https://pesquisa.bvsalud.org/portal/resource/pt/sea-225710 (accessed on 29 July 2024).
- Brady, G.C.; Carding, P.N.; Bhosle, J.; Roe, J.W. Contemporary management of voice and swallowing disorders in patients with advanced lung cancer. Curr. Opin. Otolaryngol. Head Neck Surg. 2015, 23, 191–196. [Google Scholar] [CrossRef] [PubMed]
- Mandal, A.K.J.; Htet, Z.Y.; Missouris, C.G. Pneumopericardium Complicating Esophageal Cancer. ACG Case Rep. J. 2019, 6, 1–2. [Google Scholar] [CrossRef] [PubMed]
- Gaspar, L.E. Brain metastases in lung cancer. Expert Rev. Anticancer Ther. 2004, 4, 259–270. [Google Scholar] [CrossRef] [PubMed]
- Goncalves, P.H.; Peterson, S.L.; Vigneau, F.D.; Shore, R.D.; Quarshie, W.O.; Islam, K.; Schwartz, AG.; Wozniak, AJ.; Gadgeel, S.M. Risk of brain metastases in patients with nonmetastatic lung cancer: Analysis of the Metropolitan Detroit Surveillance, Epidemiology, and End Results (SEER) data. Cancer 2016, 122, 1921–1927. [Google Scholar] [CrossRef] [PubMed]
- Confavreux, C.B.; Pialat, J.B.; Bellière, A.; Brevet, M.; Decroisette, C.; Tescaru, A.; Wegrzyn, J.; Barrey, C.; Mornex, F.; Souquet, PJ.; et al. Bone metastases from lung cancer: A paradigm for multidisciplinary onco-rheumatology management. Jt. Bone Spine 2019, 86, 185–194. [Google Scholar] [CrossRef] [PubMed]
- Kanaji, N.; Watanabe, N.; Kita, N.; Bandoh, S.; Tadokoro, A.; Ishii, T.; Dobashi, H.; Matsunaga, T. Paraneoplastic syndromes associated with lung cancer. World J. Clin. Oncol. 2014, 5, 197–223. [Google Scholar] [CrossRef] [PubMed]
- Hauber, H.P. Paraneoplastic syndromes in lung cancer. Pneumologie 2011, 65, 347–358. [Google Scholar] [CrossRef] [PubMed]
- Kim, E.S.; Herbst, R.S.; Wistuba, I.I.; Lee, J.J.; Blumenschein, G.R., Jr.; Tsao, A.; Stewart, D.J.; Hicks, M.E.; Erasmus, J., Jr.; Gupta, S.; et al. The BATTLE trial: Personalizing therapy for lung cancer. Cancer Discov. 2011, 1, 44–53. [Google Scholar] [CrossRef]
- Trial watch: Herbst, R.S. Adaptive BATTLE trial uses biomarkers to guide lung cancer treatment. Nat. Rev. Drug. Discov. 2010, 9, 423. [Google Scholar]
- Liu, S.; Lee, J.J. An overview of the design and conduct of the BATTLE trials. Chin. Clin. Oncol. 2015, 33, 6. [Google Scholar]
- So, W.V.; Dejardin, D.; Rossmann, E.; Charo, J. Predictive biomarkers for PD-1/PD-L1 checkpoint inhibitor response in NSCLC: An analysis of clinical trial and real-world data. J. Immunother. Cancer 2023, 11, e006464. [Google Scholar] [CrossRef] [PubMed]
- Feinstein, T.; Legaspi, G.; Duprez, S.; Huang, L.; Mohanlal, R. Prognostic value of baseline immune suppressive biomarkers to select non-small cell lung cancer (NSCLC) patients (pts) likely to benefit from the plinabulin/docetaxel (Plin/Doc) combination. J. Clin. Oncol. 2023, 41, e21018. [Google Scholar] [CrossRef]
- Blumenschein, G.R., Jr.; Saintigny, P.; Liu, S.; Kim, E.S.; Tsao, A.S.; Herbst, R.S.; Alden, C.; Lee, J.J.; Tang, X.; Stewart, D.J.; et al. Comprehensive biomarker analysis and final efficacy results of sorafenib in the BATTLE trial. Clin. Cancer Res. 2013, 19, 6967–6975. [Google Scholar] [CrossRef] [PubMed]
- Guo, L.; Song, B.; Xiao, J.; Lin, H.; Chen, J.; Su, X. The Prognostic Value of Biomarkers on Detecting Non-Small Cell Lung Cancer in a Chinese Elderly Population. Int. J. Gen. Med. 2021, 14, 5279–5286. [Google Scholar] [CrossRef] [PubMed]
- Giommoni, E.; Pillozzi, S.; Ottanelli, C.; Cosso, F.; Caliman, E.; Mazzoni, F.; Fancelli, S.; Lavacchi, D.; Brugia, M.; Pellegrini, E.; et al. Eosinophil count and immune-related adverse events (irAEs) as predictive biomarkers of survival in patients with NSCLC treated with ICIs. J. Clin. Oncol. 2023, 41, e21144. [Google Scholar] [CrossRef]
- Bonomi, P.D.; Gandara, D.; Hirsch, F.R.; Kerr, K.M.; Obasaju, C.; Paz-Ares, L.; Bellomo, C.; Bradley, J.D.; Bunn, P.A., Jr.; Culligan, M.; et al. Predictive biomarkers for response to EGFR-directed monoclonal antibodies for advanced squamous cell lung cancer. Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. 2018, 29, 1701–1709. [Google Scholar] [CrossRef] [PubMed]
- Mascaux, C.; Feser, W.J.; Lewis, M.T.; Barón, A.E.; Coldren, C.D.; Merrick, D.T.; Kennedy, T.C.; Eckelberger, J.I.; Rozeboom, L.M.; Franklin, W.A.; et al. Endobronchial miRNAs as biomarkers in lung cancer chemoprevention. Cancer Prev. Res. 2013, 6, 100–108. [Google Scholar] [CrossRef] [PubMed]
- Saito, M.; Yoshino, T. Clinical development of biomarkers for personalized medicine. Nihon Rinsho Jpn. J. Clin. Med. 2010, 68, 1111–1116. [Google Scholar]
- Carrigan, P.; Krahn, T. Impact of Biomarkers on Personalized Medicine. Handb. Exp. Pharmacol. 2016, 232, 285–311. [Google Scholar]
- Villalobos, P.; Wistuba, I.I. Lung Cancer Biomarkers. Hematol./Oncol. Clin. N. Am. 2017, 31, 13–29. [Google Scholar] [CrossRef] [PubMed]
- Schneider, J. Tumor markers in detection of lung cancer. Adv. Clin. Chem. 2006, 42, 1–41. [Google Scholar] [PubMed]
- Sears, C.R.; Mazzone, P.J. Biomarkers in Lung Cancer. Clin. Chest Med. 2020, 41, 115–127. [Google Scholar] [CrossRef] [PubMed]
- Zhang, C.; Sun, C.; Zhao, Y.; Wang, Q.; Guo, J.; Ye, B.; Yu, G. Overview of MicroRNAs as Diagnostic and Prognostic Biomarkers for High-Incidence Cancers in 2021. Int. J. Mol. Sci. 2022, 23, 11389. [Google Scholar] [CrossRef] [PubMed]
- Zheng, D.; Haddadin, S.; Wang, Y.; Gu, L.Q.; Perry, M.C.; Freter, C.E.; Wang, M.X. Plasma microRNAs as novel biomarkers for early detection of lung cancer. Int. J. Clin. Exp. Pathol. 2011, 4, 575–586. [Google Scholar] [PubMed]
- Gale, D.; Heider, K.; Ruiz-Valdepenas, A.; Hackinger, S.; Perry, M.; Marsico, G.; Rundell, V.; Wulff, J.; Sharma, G.; Knock, H.; et al. Residual ctDNA after treatment predicts early relapse in patients with early-stage non-small cell lung cancer. Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. 2022, 33, 500–510. [Google Scholar] [CrossRef] [PubMed]
- Horvath, S. DNA methylation age of human tissues and cell types. Genome Biol. 2013, 14, R115. [Google Scholar] [CrossRef] [PubMed]
- Jones, P.A.; Baylin, S.B. The epigenomics of cancer. Cell 2007, 128, 683–692. [Google Scholar] [CrossRef] [PubMed]
- Jung, S.Y.; Park, D.I.; Park, M.R.; Jung, S.S.; Kim, J.O.; Kim, S.Y.; Lee, J.E. Clinical Characteristics of Patients Older than 76 with Lung Cancer. Korean J. Med. 2012, 82, 562–568. [Google Scholar] [CrossRef]
- Weiss, J.; Langer, C. Treatment of lung cancer in the elderly patient. Semin. Respir. Crit. Care Med. 2013, 34, 802–809. [Google Scholar]
- Venuta, F.; Diso, D.; Onorati, I.; Anile, M.; Mantovani, S.; Rendina, E.A. Lung cancer in elderly patients. J. Thorac. Dis. 2016, 8 (Suppl. S11), S908–S914. [Google Scholar] [CrossRef] [PubMed]
- Owonikoko, T.K.; Ramalingam, S.S.; Khuri, F.R. Lung cancer in the elderly: What’s age got to do with it? Oncology 2010, 24, 1120. [Google Scholar] [PubMed]
- Demers, L.; Desrosiers, J.; Ska, B.; Wolfson, C.; Nikolova, R.; Pervieux, I.; Auger, C. Assembling a toolkit to measure geriatric rehabilitation outcomes. Am. J. Phys. Med. Rehabil. 2005, 84, 460–472. [Google Scholar] [CrossRef] [PubMed]
- Carrillo, C.B.; Barr, C.; George, S. Cognitive Status and Outcomes of Older People in Orthopedic Rehabilitation? A Retrospective-Cohort Study. Geriatrics 2020, 5, 14. [Google Scholar] [CrossRef] [PubMed]
- Carpenter, C.R.; Mooijaart, S.P. Geriatric Screeners 2.0: Time for a Paradigm Shift in Emergency Department Vulnerability Research. J. Am. Geriatr. Soc. 2020, 68, 1402–1405. [Google Scholar] [CrossRef] [PubMed]
- Kenis, C.; Heeren, P.; Bron, D.; Decoster, L.; Moor, R.; Pepersack, T.; Langenaeken, C.; Rasschaert, M.; Jerusalem, G.; Van Rijswijk, R.; et al. Multicenter implementation of geriatric assessment in Belgian patients with cancer: A survey on treating physicians’ general experiences and expectations. J. Geriatr. Oncol. 2014, 5, 431–438. [Google Scholar] [CrossRef] [PubMed]
- Kenis, C.; Decoster, L.; Van Puyvelde, K.; De Grève, J.; Conings, G.; Milisen, K.; Flamaing, J.; Lobelle, J.P.; Wildiers, H. Performance of two geriatric screening tools in older patients with cancer. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2014, 32, 19–26. [Google Scholar] [CrossRef] [PubMed]
- Hirpara, D.H.; Kidane, B.; Rogalla, P.; Cypel, M.; de Perrot, M.; Keshavjee, S.; Pierre, A.; Waddell, T.; Yasufuku, K.; Darling, G.E. Frailty assessment prior to thoracic surgery for lung or esophageal cancer: A feasibility study. Support. Care Cancer Off. J. Multinatl. Assoc. Support. Care Cancer 2019, 27, 1535–1540. [Google Scholar] [CrossRef] [PubMed]
- Baitar, A.; Van Fraeyenhove, F.; Vandebroek, A.; De Droogh, E.; Galdermans, D.; Mebis, J.; Schrijvers, D. Evaluation of the Groningen Frailty Indicator and the G8 questionnaire as screening tools for frailty in older patients with cancer. J. Geriatr. Oncol. 2013, 4, 32–38. [Google Scholar] [CrossRef]
- Smets, I.H.; Kempen, G.I.; Janssen-Heijnen, M.L.; Deckx, L.; Buntinx, F.J.; van den Akker, M. Four screening instruments for frailty in older patients with and without cancer: A diagnostic study. BMC Geriatr. 2014, 14, 26. [Google Scholar] [CrossRef]
- Owusu, C.; Berger, N.A. Comprehensive geriatric assessment in the older cancer patient: Coming of age in clinical cancer care. Clin. Pract. 2014, 11, 749–762. [Google Scholar] [CrossRef] [PubMed]
- Raynaud, C.; Le Caer, H.; Borget, I.; Jullian, H.; Locher, C.; Chouaid, C. Comprehensive geriatric assessment and complications after resection for lung cancer. Rev. Des Mal. Respir. 2010, 27, 483–488. [Google Scholar] [CrossRef] [PubMed]
- Schulkes, K.J.; Hamaker, M.E.; van den Bos, F.; van Elden, L.J. Relevance of a Geriatric Assessment for Elderly Patients with Lung Cancer-A Systematic Review. Clin. Lung Cancer 2016, 17, 341–349.e3. [Google Scholar] [CrossRef] [PubMed]
- Schulkes, K.J.; Souwer, E.T.; Hamaker, M.E.; Codrington, H.; van der Sar-van der Brugge, S.; Lammers, J.J.; Portielje, J.E; van Elden, L.J.; van den Bos, F. The Effect of A Geriatric Assessment on Treatment Decisions for Patients with Lung Cancer. Lung 2017, 195, 225–231. [Google Scholar] [CrossRef] [PubMed]
- Cella, D. The Functional Assessment of Cancer Therapy-Lung and Lung Cancer Subscale assess quality of life and meaningful symptom improvement in lung cancer. Semin. Oncol. 2004, 31 (Suppl. S9), 11–15. [Google Scholar] [CrossRef] [PubMed]
- Heyes, A. Clinical trial experience with Functional Assessment of Cancer Therapy-Lung in conventional and targeted non-small cell lung cancer therapy. Semin. Oncol. 2004, 31 (Suppl. S9), 16–22. [Google Scholar] [CrossRef] [PubMed]
- Schmidt, K.; Vogt, L.; Thiel, C.; Jäger, E.; Banzer, W. Validity of the six-minute walk test in cancer patients. Int. J. Sports Med. 2013, 34, 631–636. [Google Scholar] [CrossRef] [PubMed]
- Dy, S.M.; Gupta, A.; Waldfogel, J.M.; Sharma, R.; Zhang, A.; Feliciano, J.L.; Sedhom, R.; Day, J.; Gersten, R.A.; Davidson, P.M.; et al. AHRQ Comparative Effectiveness Reviews. Interventions for Breathlessness in Patients with Advanced Cancer; Agency for Healthcare Research and Quality (US): Rockville, MD, USA, 2020. [Google Scholar]
- Wesolowski, S.; Orlowski, T.M.; Kram, M. The 6-min walk test in the functional evaluation of patients with lung cancer qualified for lobectomy. Interact. Cardiovasc. Thorac. Surg. 2020, 30, 559–564. [Google Scholar] [CrossRef] [PubMed]
- Troosters, T.; Gosselink, R.; Decramer, M. Six minute walking distance in healthy elderly subjects. Eur. Respir. J. 1999, 14, 270–274. [Google Scholar] [CrossRef]
- Gironés, R.; Torregrosa, D.; Maestu, I.; Gomez-Codina, J.; Tenías, J.M.; Costa, R.R. Comprehensive Geriatric Assessment (CGA) of elderly lung cancer patients: A single-center experience. J. Geriatr. Oncol. 2012, 3, 98–103. [Google Scholar] [CrossRef]
- Hirpara, D.H.; Gupta, V.; Brown, L.; Kidane, B. Patient-reported outcomes in lung and esophageal cancer. J. Thorac. Dis. 2019, 11 (Suppl S4), S509–S514. [Google Scholar] [CrossRef] [PubMed]
- Eton, D.T.; Yost, K.J.; Cella, D. Future trends in patient-reported outcomes assessment for patients with advanced-stage lung cancer receiving targeted therapy. Clin. Lung Cancer 2006, 8, 99–109. [Google Scholar] [CrossRef] [PubMed]
- Brønserud, M.M.; Iachina, M.; Green, A.; Groenvold, M.; Jakobsen, E. Patient reported outcome data as performance indicators in surgically treated lung cancer patients. Lung Cancer 2019, 130, 143–148. [Google Scholar] [CrossRef] [PubMed]
- Fan, J.; Worster, A.; Fernandes, C.M. Predictive validity of the triage risk screening tool for elderly patients in a Canadian emergency department. Am. J. Emerg. Med. 2006, 24, 540–544. [Google Scholar] [CrossRef]
- Meyer, J.M.; Nasrallah, H.A. Medical Illness and Schizophrenia; American Psychiatric Pub: Washington, DC, USA, 2009. [Google Scholar]
Acronym | Biomarker | Description |
---|---|---|
EGFR | Epidermal Growth Factor Receptor | Mutations in the EGFR gene are common in non-small-cell lung cancer (NSCLC) and are important for selecting patients for EGFR tyrosine kinase inhibitor therapy. |
ALK | Anaplastic Lymphoma Kinase | Rearrangements in the ALK gene are found in a subset of NSCLC patients, and these patients may benefit from ALK inhibitors. |
KRAS | Kirsten Rat Sarcoma Viral Oncogene | KRAS mutations are common in lung cancer and have been associated with resistance to certain therapies, although new treatments targeting specific KRAS mutations are emerging. |
ROS1 | C-ros Oncogene 1 | Like ALK, ROS1 rearrangements can predict responsiveness to specific targeted therapies in NSCLC. |
BRAF | Proto-Oncogene B-Raf | Mutations in the BRAF gene, particularly V600E, can be targeted with specific inhibitors in NSCLC. |
PD-L1 | Programmed Death-Ligand 1 | The expression level of PD-L1 can predict the response to PD-1/PD-L1 checkpoint inhibitors in lung cancer. |
HER2 | Human Epidermal Growth Factor Receptor 2 | While less common, HER2 mutations can be targeted with specific therapies in NSCLC. |
MET | Mesenchymal–Epithelial Transition | MET exon 14 skipping mutations and MET amplification can influence treatment options in NSCLC. |
RET | Rearranged during transfection | Rearrangements in the RET gene can be targeted with RET inhibitors in NSCLC. |
P53 | Tumor Suppression Gene P 53 | Mutations in P53 are common in lung cancer and can have prognostic significance. |
TMB | Tumor Mutational Burden | High TMB can predict responsiveness to immunotherapy in some lung cancer settings. |
MSI | Microsatellite Instability | Although rarer in lung cancer, these biomarkers can predict response to immunotherapy [11]. |
dMMR | Mismatch Repair Deficiency | Although rarer in lung cancer, these biomarkers can predict response to immunotherapy [11]. |
Items | Possible Responses (Score) |
---|---|
| 0 = severe decrease in food intake |
1 = moderate decrease in food intake | |
2 = no decrease in food intake | |
| 0 = weight loss > 3 kg |
1 = does not know | |
2 = weight loss between 1 and 3 kg | |
3 = no weight loss | |
| 3 = no weight loss |
0 = bed or chair bound | |
1 = able to get out of bed/chair but does not go out | |
2 = goes out | |
| 0 = severe dementia or depression |
1 = mild dementia | |
2 = no psychological problems | |
| 0 = BMI < 19 |
1 = BMI 19 to <21 | |
2 = BMI 21 to <23 | |
3 = BMI ≥ 23 | |
| 0 = yes |
1 = no | |
| 0.0 = not as good |
0.5 = does not know | |
1.0 = as good | |
2.0 = better | |
Age | 0: >85 |
1: 80–95 | |
2: <80 | |
Total score | 0–17 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Pîslaru, A.I.; Albișteanu, S.-M.; Ilie, A.C.; Ștefaniu, R.; Mârza, A.; Moscaliuc, Ș.; Nicoară, M.; Turcu, A.-M.; Grigoraș, G.; Alexa, I.D. Lung Cancer: New Directions in Senior Patients Assessment. Geriatrics 2024, 9, 101. https://doi.org/10.3390/geriatrics9040101
Pîslaru AI, Albișteanu S-M, Ilie AC, Ștefaniu R, Mârza A, Moscaliuc Ș, Nicoară M, Turcu A-M, Grigoraș G, Alexa ID. Lung Cancer: New Directions in Senior Patients Assessment. Geriatrics. 2024; 9(4):101. https://doi.org/10.3390/geriatrics9040101
Chicago/Turabian StylePîslaru, Anca Iuliana, Sabinne-Marie Albișteanu, Adina Carmen Ilie, Ramona Ștefaniu, Aurelia Mârza, Ștefan Moscaliuc, Mălina Nicoară, Ana-Maria Turcu, Gabriela Grigoraș, and Ioana Dana Alexa. 2024. "Lung Cancer: New Directions in Senior Patients Assessment" Geriatrics 9, no. 4: 101. https://doi.org/10.3390/geriatrics9040101
APA StylePîslaru, A. I., Albișteanu, S. -M., Ilie, A. C., Ștefaniu, R., Mârza, A., Moscaliuc, Ș., Nicoară, M., Turcu, A. -M., Grigoraș, G., & Alexa, I. D. (2024). Lung Cancer: New Directions in Senior Patients Assessment. Geriatrics, 9(4), 101. https://doi.org/10.3390/geriatrics9040101